Bloomberg the Company

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

Merrill Downgrades Biogen Rating

Merrill Lynch downgraded its investment recommendation on Biogen Corp. (BGEN) to near-term and long-term neutral from accumulate.

Analyst Eric Hecht says the downgrade is based on two factors. First, he says his major concern is that Serona S.A.'s multiple sclerosis drug Rebif will be highly competitive to Biogen's Avonex. His second concern relates to Biogen's delay of releasing information regarding its psoriasis medicine Amevive. Hecht slashed the 18% growth rate to 7%.

The Aging of Abercrombie & Fitch
blog comments powered by Disqus